Introduction
The ovariectomized mouse uterus exhibits rapid biochemical and biological responses to estrogens that have been extensively studied and charac terized (Katzenellenbogen et al. 1979) . Using this mouse model, we previ ously evaluated transcript responses by micro array and identified several thousand genes with transcripts that are increased or decreased following estrogen treatment (Hewitt et al. 2003) . Natural and synthetic estrogenic substances are known to exhibit characteristic degrees of activity. For example, longacting estrogens, such as estradiol (E 2 ) and diethylstil bestrol (DES), elicit biological responses early (within 1-2 hr) and persist, resulting in later responses (24-72 hr) that lead to maximal uterine growth. In contrast, shortacting estro gens, such as estriol (E 3 ), match longacting estrogens in eliciting the early responses, but because of their pharmaco kinetics they do not persist, and thus in vivo responses charac teristic of later end points are blunted (Clark and Markaverich 1984; Katzenellenbogen 1984) . However, E 3 is able to match E 2 in in vitro systems: For example, E 3 is able to stimulate MCF7 cell growth because culture conditions lack E 3 metabolic clearing (Katzenellenbogen 1984) . The xeno estrogens bisphenol A (BPA) and 2,2bis(phydroxyphenyl)1,1,1trichloro ethane (HPTE) elicited uterine transcription patterns similar to those of the proven short acting estrogen E 3 (Hewitt and Korach 2011; Klotz et al. 2000) . Responses were highly correlated to those of E 2 at 2 hr but were attenuated and less correlated to E 2 at 24 hr (Hewitt and Korach 2011) . We confirmed the shortacting estrogenlike activities of BPA and HPTE by observing uterine biological responses that were charac teristic of short acting estrogens. These end points included uterine weight increases that were attenuated after 72 hr (3 days) and decreased induction of epithelial cell DNA synthesis after 24 hr (Hewitt and Korach 2011) .
Recognizing not only the potential estro genic activity of endocrinedisrupting chemi cals (EDCs) but also determining whether they have shortacting or sustained actions is important for evaluation of risks to humans and wildlife. Because of their more sustained activity (Hewitt and Korach 2011; Safe et al. 2001) , longacting estrogens are more likely to affect estrogensensitive tissues and thus might be considered of greater risk in terms of their impacts on exposed populations (Safe et al. 2001) . In contrast, individuals who lack endogenous longacting estrogens, including prepubertal girls and post menopausal women, might also exhibit susceptibility to shortacting estrogens. It is therefore important to develop tools predicting estrogenicity and also potential to elicit sustained responses. In the study of cancer, biomarker panels of transcripts have been developed as tools for diagnosis and for selection of treatments most likely to be effective (Gormley et al. 2007 ). In the present study, we aimed to use the wellcharacterized ovariectomized mouse uterus model to generate a screen that incorporates phenotypic estrogenresponse end points and transcrip tional biomarkers that distinguish estrogenic characteristics. We hope our approach will allow more detailed assessment of substances than do in vitro high throughput screens but without undertaking extensive animal studies or comprehensive genomic analyses. We developed panels of transcripts for use as biomarkers and pheno typic uterine responses to assess the activity of candidate compounds in terms of estrogenic activity and classifica tion as short versus longacting estrogen. We analyzed uterine microarray data sets using the EPIG tool (Extracting Patterns and Identifying coexpressed Genes; Chou et al. 2007 ), and we identified patterns charac teristic of short acting (only 2 hr) or longacting (both 2 hr and 24 hr) estrogen response. To increase the Background: Concerns regarding potential endocrine-disrupting chemicals (EDCs) have led to a need for methods to evaluate candidate estrogenic chemicals. Our previous evaluations of two such EDCs revealed a response similar to that of estradiol (E 2 ) at 2 hr, but a less robust response at 24 hr, similar to the short-acting estrogen estriol (E 3 ). oBjectives: Microarray analysis using tools to recognize patterns of response have been utilized in the cancer field to develop biomarker panels of transcripts for diagnosis and selection of treatments most likely to be effective. Biological effects elicited by long-versus short-acting estrogens greatly affect the risks associated with exposures; therefore, we sought to develop tools to predict the ability of chemicals to maintain estrogenic responses. Methods: We used biological end points in uterine tissue and a signature pattern-recognizing tool that identified coexpressed transcripts to develop and test a panel of transcripts in order to classify potentially estrogenic compounds using an in vivo system. The end points used are relevant to uterine tissue, but the resulting classification of the compounds is important for other sensitive tissues and species. results: We evaluated biological and transcriptional end points with proven short-and long-acting estrogens and verified the use of our approach using a phytoestrogen. With our model, we were able to classify the diarylheptanoid D3 as a short-acting estrogen. conclusions: We have developed a panel of transcripts as biomarkers which, together with biological end points, might be used to screen and evaluate potentially estrogenic chemicals and infer mode of activity. power of validation of potential biomarker transcripts, we used biological end points including uterine weight, proliferation and/or apoptosis of epithelial cells, increase in luminal epithelial cell height, and induction of apoptosis inhibitor, thus providing pheno typic anchoring to support transcriptional responses. We identified panels of 50 genes each at 2 or 24 hr using a combined analysis of variance (ANOVA) and principal component analysis (PCA) approach, and we validated the panels by establishing activity of a candidate compound. The use of these biomarkers and response end points (summarized in Table 1 ) will allow evalua tion of potential estrogenic mechanisms for chemicals of environmental concern in a biological system. The diaryl heptanoid D3 [(3R)1,7diphenyl(4E,6E) 4,6heptadien3ol], a natural phyto estrogen isolated from an indigenous plant [Curcuma comosa Roxb. (Zingiberaceae family)] used by post menopausal women in Thailand, was previously charac terized to exhibit estrogen like activity in the uterus with a short acting biological action compared with E 2 (Winuthayanon et al. 2009 (Winuthayanon et al. , 2013 . Therefore, we used D3 as a candidate to test our panel.
Materials and Methods
Uterine bioassays. Mice were housed three to five per cage in static micro isolator solid bottom cages (Super Mouse 750™ cages; Lab Products) on autoclaved hardwood bedding (Sanichips; PJ Murphy Forest Products Corp.) and maintained on a 12:12hr light:dark cycle at 22 ± 0.5°C and relative humidity of 40-60%. Mice were provided with autoclaved rodent diet (NIH31; Zeigler Brothers) and reverseosmosis-treated deion ized water ad libitum. All procedures were reviewed and approved by the National Institute of Environmental Health Sciences Animal Care and Use Committee. All animals were housed, cared for, and used in compliance with the Guide for the Care and Use of Laboratory Animals (National Research Council 2011) in a program accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. Animals were treated humanely and with regard for allevia tion of suffering according to NIEHS Animal Care and Use Committee Guidelines and in compliance with a NIEHSapproved animal protocol. Ovariectomized adult C57BL/6 mice (n = 211; 8-10 weeks of age) were obtained from Charles River Laboratories and shipped to the NIEHS facility. Animals were then housed five per cage for 10-14 days after surgery to clear circulating ovarian hormones before treatment began. Mice were assigned to treatment groups by cage mates, or in cases where fewer than five per goup were used, mice were divided by randomly removing some mice and combining them in a new cage.
For 2 and 24hr samples [24 hr for uterine weight, 5ethynyl2´deoxyuridine (EdU) incorporation, and reversetranscrip tion polymerase chain reaction (RTPCR); 2 hr for RTPCR], mice were injected with vehicle [100 μL sterile saline (0.85% NaCl) plus 0.1% ethanol (n = 5)]; E 2 (Steraloids; 2 hr, n = 4; 24 hr, n = 5), E 3 (Steraloids; 2 hr, n = 4; 24 hr, n =5), or DES (Sigma; 24 hr only; n = 3), 1mg/mL 100% ethanol (EtOH) stock solution diluted in saline to a concentration of 250 ng/100 μL; or 4,4´,4´´(4propyl[1H]pyrazole1,3,5 triyl)trisphenol (PPT; Tocris Bioscience; 24 hr only, n = 3) 50mg/mL 100% EtOH stock solution diluted to a concen tration of 250 μg in 100 μL saline + 10% Cremaphor EL (Sigma). Treatments were adminis tered by intra peritoneal injection.
The diarylheptanoid D3 was isolated and administered as previously described (Suksamrarn et al. 2008; Winuthayanon et al. 2009 Winuthayanon et al. , 2013 . For the D3 experiments, mice were treated with sesame oil (Sigma) plus 10% EtOH (vehicle; n = 5); D3 [250mg/mL 100% EtOH stock solution diluted to a concentration of 2.5 mg/100 μL sesame oil (2 hr, n = 4; 24 hr, n = 7)]; or E 2 [1mg/mL 100% EtOH stock solution diluted in sesame oil with added ethanol to a concentration of 250 ng E 2 in 100 μL sesame oil plus 10% ethanol (2 hr, n = 4; 24 hr, n = 7)]. Treatments were adminis tered by subcutaneous injection. Doses of all compounds were selected based on the minimum dose required to induce optimal uterine responses. For E 2 , DES, E 3 , and D3, see Supplemental Material, Figure S1 . The PPT dose is based on responses reported by Sinkevicius et al. (2008) .
For 2hr experiments, treatments were given without regard to time of day. For all 24hr experiments, all injections and collec tions were done in the morning. EdU (2 mg in 100 μL phosphatebuffered saline; Life Technologies) was injected intra peritoneally 22 hr after hormone injections, and uterine tissue was collected 2 hr later (24 hr after hormone treatment). For 72hr (3day) end points (vehicle, n = 7; E 2 , n = 7; E 3 , n = 4; DES, n = 4; PPT, n = 4; and for D3 experiments (vehicle, n = 8; E 2 , n = 8; D3, n = 8), the same concentrations were used as for 24hr end points, but all were diluted in sesame oil (Sigma) and injected subcutane ously each day for 3 days. Injections for 72hr experiments were initiated without regard for time of day, but were always adminis tered 24 hr apart, and uterine tissues were collected on the fourth day. For both 24hr and 72hr experiments, uterine tissue was weighed, with a portion of one horn fixed in 10% formalin (Fisher) and the remainder snap frozen in liquid nitrogen. For 2hr experi ments, uterine tissue was snap frozen in liquid nitrogen. Frozen uterine tissue was processed for RNA analysis by realtime RTPCR as previously described (Hewitt et al. 2003) . We used at least three animals per group based on previous studies indicating that significant changes in end points are likely to be detected (Hewitt and Korach 2011) .
Fixed tissue was processed either to detect incorporated EdU using the ClickIT Kit (Life Technologies) or to indicate terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)positive apoptotic cells using the ApopTag Plus Peroxidase In Situ Apoptosis Kit (catalog no. S7101; Millipore), both methods described previously by Winuthayanon et al. (2010) . Image analysis to evaluate cell proliferation and apoptosis was completed on transverse sections of EdU and TUNEL slides scanned with an Aperio Scanscope XT Digital Slide Scanner (Leica Biosystems) and viewed using an Aperio® ImageScope v. 12.0.1.5027 (Aperio Technologies Inc.). We determined percent positive EdU staining by counting total and EdU Alexafluor 488-positive uterine luminal cells within the total uterine luminal area. The total uterine luminal area was selected by outlining the basement membrane of the uterine luminal epithelium. The percentage of luminal cells that were TUNEL positive was determined by counting the number of TUNELpositive cells per total epithe lial cells in six regions of the uterine lumen (300-800 cells per slide). Luminal epithelial cell height (LEH) was measured in five areas per transverse section using the Ruler tool in ImageScope™. Data files were exported to Excel™ (v.14.3.9; Microsoft) and compiled into a single worksheet.
Microarray analyses. We used data from previous microarray studies for pattern analysis [Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) accession Tables S1 and  S2 ]. Data from the GEO database included vehicle controls (11 samples), E 2 (13 samples), E 3 (6 samples), DES (4 samples), and PPT (4 samples) for 2 or 24 hr. All were gener ated using Agilent mouse 4 × 44K array chips (Agilent Technologies), and data were acquired and analyzed as described previously (Hewitt and Korach 2011; Hewitt et al. 2009 Hewitt et al. , 2010 Hewitt et al. , 2012 . EPIG analysis and derivation of biomarker panels. Batchcorrected microarray data sets (see Supplemental Material, "EPIG Analysis" and Figure S4 ) were analyzed using the EPIG tool (Chou et al. 2007 ) resulting in 16 patterns ( Figure 1A ,B). Probes that could distinguish estrogenic from non estrogenic treatments (2 hr; 50 probes) or longacting from shortacting estrogens (24 hr; 50 probes) were derived as described in Supplemental Material, "Deriving biomarker panels." Hierarchical clustering of the expression of the 2hr or 24hr probes with estrogens validated their selection (see Supplemental Material, Figure S2 and Tables S3 and S4) .
RT-PCR and NanoString screen. We selected probes to test the 2hr and 24hr biosets by RTPCR by first combining the 50 probe panels validated above (see Supplemental Material, Figure S2 ) with 26 additional 2hr probes or 12 additional 24hr probes covering RTPCR primer sets for previously studied estrogenresponsive transcripts, and these probes were analyzed using Ingenuity Pathway Analysis (http:// www.ingenuity.com/products/ipa). Probes that duplicated gene names and genes that represented the same biological function were consolidated. Genes for RTPCR vali dation were then selected using a random number generator. For NanoString analysis, 129 biomarker probes plus 9 housekeeping probes were submitted to NanoString Technologies for CodeSet design, and RNA samples were shipped to NanoString for processing and analysis. Briefly, 100 ng of each RNA sample was added to the CodeSet in hybridization buffer and incubated at 65°C for 16 hr. The CodeSet consists of Reporter and Capture probes that hybridize to the target sequences of interest, forming a tripartite complex. Assays were purified using the Prep Station software (High Sensitivity Protocol; NanoString), and data were collected using the GEN2 Digital Analyzer (NanoString), and raw counts were provided. Raw counts were then were normalized using nSolver software (NanoString) and exported into Partek Genomics Suite 6.6 (Partek Inc.) for clustering. Normalized values are presented in Supplemental Material, Supplemental XLSX, Table S5 .
Statistical analysis for biological end points. Data for realtime RTPCR as well as quantification of EdU and TUNEL positive cells and uterine LEH are presented as mean ± SE. GraphPad Prism 6.0 for Windows (http://www.graphpad.com/ scientificsoftware/prism/) was used for statis tical analysis. Differences were considered significant when p < 0.05, using ANOVA with Tukey multiple comparisons post hoc, unless otherwise indicated.
Results
Biological end points. We compared prolifera tion of uterine epithelial cells-a hallmark of estrogenic response-in ovariectomized mice treated with E 2 , E 3 , DES (a synthetic estrogen), or PPT [a synthetic estrogen receptor α (ERα)-selective agonist]. Treatment with all of the estrogens resulted in an increase in epithelial cells in S phase, as reflected by incorporation of the thymi dine triphosphate analog EdU (Figure 2A,B) . At the 24hr time point, uterine wet weights were increased by E 2 , E 3 , or DES (p < 0.05), but not significantly by PPT ( Figure 2C ). However, after 3 days of treatment, uterine weight was not significantly increased by E 3 ; however, E 2 or DES treatment led to a robust uterine weight increase (p < 0.0001), whereas PPT caused an increase (p < 0.001) that was significantly lower than the increase induced by E 2 or DES (p < 0.001) ( Figure 2D ). In the 72hr bioassay, E 2 , E 3 , DES, and PPT treat ment resulted in increased epithelial thick ness and cell height (p < 0.001; Figure 2E ); however, PPT and E 3 increased the epithe lial thickness significantly less than did E 2 (p < 0.001 vs. E 2 ; Figure 2E ). Three days of E 3 treatment did not induce transcripts of either the apoptosis inhibitor Birc1a (baculo viral IAP repeatcontaining protein 1a) or the epithelial cell secretory protein Ltf (lacto ferrin), whereas E 2 , DES, and PPT induced both of these ( Figure 2F ,G). In addition, E 3 and PPT exhibited significantly more TUNELpositive epithelial cells than E 2 or DES (p < 0.05; Figure 2H ,I), indicating increased apoptosis.
Bioinformatic analysis to develop transcript panels. Toward our goal of developing panels of biomarker transcripts, which, in combination with these biological end points, might be used to screen for potential estro genic activity of candidate chemicals, we used the EPIG tool (Chou et al. 2007 ) to identify patterns of gene expression in our microarray data sets. Because our data sets did not include sufficient numbers of test compounds for derivation of training and validation nor did they include test data sets to appropriately perform a prediction, we utilized a phenotypic anchoring approach. We correlated gene expression according to the samples defined by the strength of estrogen response. The statistical framework of this correlation has been well described (Chou et al. 2007 ) and has statistical proper ties that are similar to an ANOVA model (sample variances), ttest (group compari sons), and signal processing (signaltonoise thresholding). However, our approach also leverages the biological responses of the samples within a group, and correlation of gene expression among the groups, to extract patterns of genes that have a low probability of being detected by chance. Hence, the statistical rigor in our methodology supports the selection of these biomarker transcripts combined with these biological end points as a potential screen for estrogenic activity of candidate chemicals (Table 1 ). Figure 1A shows patterns of transcript profiles in uterine tissue from mice treated with vehicle, PPT, E 3 , DES, or E 2 for 2 or 24 hr. Each plot in Figure 1B represents one of the 16 response patterns extracted by EPIG. For example, the estrogenic compounds (E 3 , PPT, E 2 , and DES) increased the levels of the 2,481 probes in pattern 5 relative to vehicle after 2 hr, but the level of these probes returned to baseline by 24 hr. Similarly, the estrogenic compounds decreased the levels of the 2,002 probes in pattern 9 after 2 hr. The probes in these patterns could thus be used to examine whether a substance has estrogenic activity by evaluating the levels of these transcripts 2 hr after treatment. After 24 hr of treatment, E 2 or DES more robustly increased the 4,467 probes in pattern 3 relative to vehicle than did PPT or E 3 . Only E 2 or DES, but not PPT or E 3 , increased the 691 probes in pattern 7. After 24 hr of treatment, both E 2 and DES repressed the 3,311 probes in pattern 14 relative to vehicle, whereas PPT and E 3 were less effective. Therefore, longacting versus shortacting estrogens could be distinguished by evaluating the levels of transcripts from patterns 3, 7, or 14 at 24 hr after treatment. After 2 hr of treatment, all of the compounds increased the levels of the 2,191 probes in pattern 1. However, after 24 hr, only DES and E 2 maintained the increased levels of the probes, whereas the levels were lower for the shortacting estrogens. After 2 hr of treatment, all of the compounds decreased the levels of the 2,751 probes in pattern 16; however, after 24 hr, only DES and E 2 main tained the repressed levels of the probes, but the shortacting estrogens returned to the vehicle level. Therefore, probes in patterns 1 and 16 could demonstrate estrogenic response at 2 hr and distinguish shortacting from longacting estrogens at 24 hr.
Two panels, each comprising 50 probes, were selected using a combined ANOVA and PCA approach, detailed in the Supplemental Material, "Deriving biomarker panels." The (Hewitt and Korach 2011) . We used our previous micro array data sets (E 2 , E 3 , DES, BPA, HPTE, and PPT) to examine the expression of the probes in the biomarker panels. Supplemental Material, Figure S2A shows the level of the 50 probes 2 hr after treatment with E 2 , E 3 , DES, BPA, HPTE, or PPT relative to vehicle (see Supplemental Material, Supplemental XLSX, Table S6 ); all of the compounds showed responses distinct from vehicle at this time point. Supplemental Material, Figure S2B (see also Supplemental Material, Supplemental XLSX, Table S7 ) shows the 50 probes selected to distinguish longacting estrogens (E 2 and DES) from shortacting estrogens (E 3 , BPA, and HPTE). PPT was not included in the short versus longacting 24hr panel analysis, because it is an ERα selective agonist but has not been classified as short or longacting. The biological data (Figure 2 ) indicated that PPT exhibited a response between long and shortacting estrogens.
RT-PCR and validation of transcript panels. To validate our potential screening strategy, as shown in Table 1 , we evalu ated a diarylheptanoid, D3 ( Figure 3A ) (Suksamrarn et al. 2008) , which has tradi tionally been used by women in Thailand to relieve post menopausal symptoms. Studies by Winuthayanon et al. (2009 Winuthayanon et al. ( , 2013 have suggested that this compound has estrogenic properties. As a test of this concept, we used biological response end points together with probes selected from each biomarker panel. Treatment with D3 resulted in the entry of uterine epithelial cells into S phase, and EdU incorporation and uterine weight was increased to a level comparable with E 2 after 24 hr ( Figure 3B-D) . However, the uterine weight after 72 hr was lower than that reached by E 2 ( Figure 3D ) and was not statistically significant (p = 0.054), as reported in earlier studies (Winuthayanon et al. 2009 (Winuthayanon et al. , 2013 . The lower weight increase after 72 hr of treatment was reflected in increased TUNELpositive cells ( Figure 3E ,F) as well as in an attenuated LEH increase ( Figure 3G ). These biological observations are consistent with shortacting estrogenic activity. Therefore, we evaluated transcrip tional responses of selected biomarker panel transcripts after 2 or 24 hr of treatment ( Figure 4A,B) . Of the 10 transcripts from the 2hr panel we tested, 8 showed similar responses with E 2 , E 3 , or D3, but D3 did Percentage of EdU-positive cells in uterine tissue 24 hr after injection (mean ± SE; n = 5-9 mice/group). **p < 0.01 compared with V by one-way ANOVA with multiple comparisons and uncorrected Fisher's least significant difference (LSD). (C) Uterine weight 24 hr after injection (mean ± SE; n = 3-5 mice/ group). *p < 0.05, ***p < 0.001, and ****p < 0.0001, compared with V by one-way ANOVA, with multiple comparisons, with Tukey's multiple test correction. (D) Uterine weight in the 72 hr (3 day) bioassay, with uteri collected 24 hr after the last of three daily injections (mean ± SE; n = 4-7 mice/group). **p < 0.001 for PPT compared with DES or E 2 ; and ****p < 0.0001 compared with V, by one-way ANOVA, with multiple comparisons, with Tukey's multiple test correction. (E) Luminal epithelial cell height (LEH) in the 72-hr bioassay (mean ± SE; n = 4-7 mice/ group). ***p <0.001, and ****p < 0.0001 compared with V; + p < 0.0001 compared with E 2 or DES; and # p < 0.001 compared with E 2 by one-way ANOVA, with multiple comparisons, with Tukey's multiple test correction. (F) Level of RNA for the apoptosis inhibitor Birc1a measured by RT-PCR in uteri from the 72-hr bioassay (mean ± SE; n = 4-7 mice/group). ***p < 0.001, and ****p < 0.0001 compared with V by one-way ANOVA with multiple comparisons and uncorrected Fisher's LSD. (G) Ltf transcript measured by RT-PCR in uteri from the 72-hr bioassay (mean ± SE; n = 4-7 mice/group). **p < 0.01, ***p < 0.001, and **** p < 0.0001 compared with V; and + p < 0.01 for PPT compared with E 2 by one-way ANOVA, with multiple comparisons, with Tukey's multiple test correction. 
not significantly induce two of the transcripts (Cdkn1a and Stat5a) and induced Nup50 less robustly than did E 2 or E 3 ( Figure 4A ). In the 24hr panel, 2 transcripts (Ndufab1 and Gfm1) showed no regulation with any of the tested substances ( Figure 4B ). The remaining 7 transcripts either showed no response with D3 (Kifc2, Rorc, Sox4, Ccnb1, Nubp1, and Aurkb) or a response that was significant but was blunted compared with the E 2 response (Ccnb2) ( Figure 4B ). Depending on the tran script, E 3 exhibited responses similar to those of D3 (Kifc2, Rorc, and Sox4) but in some cases the response was between those of D3 and E 2 (Aurkb and Ccnb2).
The RNA samples were then analyzed using a NanoString CodeSet that included 129 biomarkers and 9 housekeeping probes. Most of the probes in each of the panels confirmed the expected patterns (see Supplemental Material, Figure S3 ), with the 2hr probes indicating regulation relative to vehicle by E 2 , E 3 or D3 (see Supplemental Material, Figure S3A ) and the 24hr panel confirming differential regulation by long versus shortacting estrogens (see Supplemental Material, Figure S3B ).
Discussion
Endocrine disruption describes a property of exogenous chemicals, either natural or manmade, that leads to perturbation of biological function via endogenous endocrine systems. These chemicals have the poten tial to greatly impact human health and the environment. However, endocrine disrup tion encompasses broad classes of chemicals that individually affect diverse biological signaling pathways. Thus, there is a need to focus on identifying which substances can affect which molecular events. In the present study, we designed a multi pronged approach that combines transcriptional and pheno typic end points in order to evaluate chemi cals suspected to affect estrogen signaling. As summarized in Table 1 , our study design included treatment of ovariectomized mice with various chemicals and collecting uteri 2 hr or 24 hr after a single injection, or 24 hr after last of three daily injections (72 hr). Substances that are estrogenic increased epithe lial cell DNA synthesis at the 24hr end point and regulated transcripts in the 2hr panel relative to vehicle or a non estrogenic chemical at the 2hr end point. Evaluation of uterine weights at the 24hr and 72hr end points could then be used to indicate whether an estrogenic substance is longacting (weight increases observed) or shortacting (weight increase is attenuated or absent). At the 24hr end point, regulation of transcripts in the 24hr panel by long versus shortacting estrogens was distinct, because shortacting estrogens exhibited impeded regulation of these transcripts. Although the end points utilized in our approach are most relevant to uterine responses, the resulting classification of compounds as short or longacting estrogens is important when evaluating potential impacts on other estrogensensitive tissues and species. In addition, our approach specifically evalu ated ERαmediated effects; ERα is essential for mouse uterine responses, revealed by the full spectrum of estrogen responsiveness exhibited by ERβnull mice (Hewitt et al. 2003) . Once substances are classified by this approach as short or longacting estrogens, subsequent analyses could gauge ERα and ERβmediated activities, as well as responses in other estrogen sensitive tissues and selective agonist versus antagonist activities. Thus, further analyses subsequent to these screens would be the next steps to evaluate whether xeno estrogens behave as selective estrogen receptor modulators such as tamoxifen (antagonistic in breast cells; agonist activity in endometrial tissue).
A previous study revealed a role for ERα in protecting epithelial cells from under going apoptosis subsequent to the initial prolifera tion response (Winuthayanon et al. 2010 ). Here, we observed apoptosis of uterine epithe lial cells as reflected by ineffective induction treatment (mean ± SE; n = 5-7 mice/group). ***p < 0.001 compared with V by one-way ANOVA with uncorrected Fisher's least significant difference (LSD). (D) Uterine weight (mean ± SE) at 24 hr after treatment (top; n = 9 mice/group) or 72 hr (24 hr after the last of three daily injections; bottom; n = 5 mice/group). ***p < 0.001, and ****p < 0.0001 compared with V, and + p < 0.01 compared with D3 by one-way ANOVA with uncorrected Fisher's LSD. (E) Representative photomicrographs showing apoptotic cells in uteri collected at 72 hr (24 hr after the last of three daily injections) as determined by the TUNEL assay (bar = 0.2 mm; the arrowhead points to a TUNEL-positive cell. (F) Percentage of TUNEL-positive cells in uteri collected at 72 hr (24 hr after the last of three daily injections; mean ± SE; n = 8 mice/group). ***p < 0.001 by unpaired t-test. (G) LEH in uteri collected at 72 hr (24 hr after the last of three daily injections; mean ± SE; n = 8 mice/group). ****p < 0.0001 compared with V, and + p < 0.001 compared with E 2 by one-way ANOVA with Tukey's multiple comparison test. (Table 1) . This suggests that, similar to what we saw after ablation of epithelial ERα (Winuthayanon et al. 2010) , shortacting estrogens are unable to maintain epithelial cell ERα activity following initial proliferation, and thus apoptosis occurs. This selective ability of longacting estrogens to induce Birc1a can initially be seen after 24 hr (data not shown) but is most apparent after 72 hr.
PPT is a known ERα selective agonist but has not previously been classified as short or long acting. In this study, some end points confirmed the estrogenic activity of PPT [DNA synthesis ( Figure 2A ) and 2hr tran script regulation (see Supplemental Material, Figure S2A )]. However, on the basis of end points, it was difficult to pin down the activity as short or long acting. Uterine weight did not increase after 24 hr, but a significant uterine weight increase occurred after 72 hr; however, this increase was attenu ated compared with that of longacting estrogens ( Figure 2D ). In addition, PPT was significantly less effective at inducing Ltf ( Figure 2G ), but it induced the Birc1a apop tosis inhibitor equally as well as longacting estrogens ( Figure 2F ), which likely explains the observed weight increase after 72 hr. Birc1a was not significantly increased by PPT after 24 hr (data not shown), and PPTtreated uteri exhibited TUNELpositive cells at a level similar to that of E 3 ( Figure 2H,I ). At 24 hr PPT increased Ltf less effectively than E 2 or DES (not shown). On all the basis of the observed end points, we classify PPT as an intermediate compound that is not a long or shortacting estrogen. We anticipate that other compounds tested in future analyses could also exhibit intermediate charac teristics, and this will be vital in predicting the risks of harmful effects, because less severe effects would be predicted for a shorteracting estrogen, but one with intermediate charac teristics might need closer consideration.
Our use of a diarylheptanoid (D3) compound isolated from a traditional Thai medicinal plant validated the approach outlined in Table 1 . Most, but not all, tran scripts from the biomarker panel probes tested by RTPCR produced the expected transcript regulation patterns with E 3 or D3. A more comprehensive analysis using the NanoString code set indicated that our biomarker panel shows promise for distin guishing estrogenicity and relative strength of endocrine disruptors. The regulation of three of the transcripts selected from the 24hr panel (Nubp1, Ndufab1, Gfm1) could not be confirmed by RTPCR. In the NanoString analysis, Nubp1 showed slight induction by E 2 , Ndufab1 was minimally regulated, and E 2 selective induction of Gfm1 regulation was readily apparent (see Supplemental Material, Supplemental XLSX, Table S5 ). Differences may reflect disparities between the probes used on the microarray platform, NanoString probes, and the primer sets employed for RTPCR.
Other approaches have focused on high throughput screens to identify potential endo crine disruptors, such as the ambitious Tox21 project at the National Toxicology Program. Tox21 aims to evaluate toxicants using robotic screens based on in vitro end points (Huang et al. 2011) . Initial efforts include Figure 4 . RT-PCR of RNA samples from mice treated for 2 or 24 hr with saline vehicle (V), E 2 , E 3 , or D3 to validate biomarker panels. Values were calculated relative to V and normalized to Rpl7 (mean ±SE; n = 3-6/group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and + p < 0.05 compared with E 2 by one-way ANOVA, with multiple comparisons, with Tukey's multiple test correction, except for Cdkn1a, with no multiple test correction (Fisher's least signicant difference test). (A) Transcripts selected from the 2-hr panel to indicate estrogenic response after 2 hr: Cdkn1a, cyclin-dependent kinase inhibitor 1A; Synpo, synaptopodin; Cyr61, cysteine rich protein 61; Inhbb, Inhibin beta-B; Socs3, suppressor of cytokine signaling 3, Stat5a, signal transducer and activator of transcription 5A; Txnip, thioredoxin interacting protein; Btbd10, BTB (POZ) domain containing 10; Cdc42se, CDC42 small effector 1; Nup50, nucleoporin 50. (B) Transcripts selected from the 24-hr panel to distinguish long-from short-acting estrogens after 24 hr: Kifc2, kinesin family member C2; Rorc, RAR-related orphan receptor gamma; Sox4, SRY-box containing gene 4; Aurkb, aurora kinase B; Ccnb1, cyclin B1; Ccnb2, cyclin B2; Nubp1, nucleotide binding protein 1; Ndufab1, NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 precursor; Gfm1, G elongation factor, mitochondrial 1 precursor. 
focus on nuclear receptor inter actions using ligand binding domains (LBD) of 10 different nuclear receptors in a Gal4based response screen of a library containing approximately 3,000 environ mentally relevant chemicals (Huang et al. 2011) . The objective of the Tox21 approach is a broad, high throughput initial evaluation to identify chemicals for further consideration. The approach we have outlined here would be a logical next step for additional evaluation of chemicals that are positive in the Tox21 nuclear receptor assay and interact with ERα. The primary informa tion obtained from the initial Tox21 screen reflects the chemical's ability to bind to and modulate the activity of the LBD of the ERα (the assay included only this portion of the receptor) and measures regulation of exog enous reporter gene activity. Such an approach lacks the inter and intra molecular interactions mediated in the context of the fulllength ERα molecule and representation of in vivo responses of endogenous genes. In addition, the Tox21 assay will not capture subtleties of estrogenic response, such as those typified by long versus shortacting estrogenic activities. Our assay scheme is useful in the context of a "second step" after an initial broad screen because the Tox21 approach is more realistic for evaluating thousands of chemicals. Our approach focuses on end points observed in mouse uterine tissue and thus may not reflect effects in other estrogen target tissues, such as breast or liver, or effects in other species. However, our panel of pheno typic and tran scription response is an appropriate partner to the broad Tox 21 approach and could be used to fine tune and finesse the mechanistic particulars and biological effects in a real whole animal context. Moggs et al. (2004) combined bioinfor matics and phenotypic anchoring approaches to a similar model, the immature mouse uterus. Although their approach is very useful toward defining transcriptional profiles that under lie phenotypic observations, it is not designed for the type of evaluation of mecha nisms of action we focused on in our study. Watanabe et al. (2004) also used the ovariecto mized mouse model to compare transcriptional responses of uterine tissue 6 hr after injection of E 2 or 2,3,7,8tetrachlorodibenzopdioxin (TCDD). In their study, some uterine tran scripts were regulated in a similar manner by E 2 or TCDD, suggesting estrogenic activity of TCDD. Many of the estrogenresponsive tran scripts showed a weaker response with TCDD. Unlike our approach, however, their screen was not a comprehensive attempt to select probes for screening. In another study Hong et al. (2006) used the immature rat model to evaluate uterine transcript profiles 24 hr after the last of three daily injections of E 2 , DES, or the endocrine disruptors BPA, genistein, and octyl phenol or nonyl phenol. Unlike the present study, the transcript profile for each substance was distinct, with few commonly regulated probes. This is especially surprising in the case of DES versus E 2 regulated tran scripts, which revealed only 126 common probes out of 555 E 2 regulated and 674 DESregulated probes (Hong et al. 2006 ), whereas we observed similar uterine responses to 72hr E 2 or DES in our model (Figure 1 ). RTPCR analysis of several transcripts revealed responses consistent with our observations, with E 2 and DES inducing transcripts at the 72hr time point and BPA showing no induc tion (Hong et al. 2006) . Naciff et al. (2002) developed a gestational exposure model to evaluate uterine transcripts in gestational day (GD) 20 rat pups 2 hr after the last daily injection of ethynyl E 2 , BPA, or genistein on GDs 11-20. The approach of Naciff et al. is complementary to ours: They sought to develop a transcriptional profile "fingerprint" as evidence of gestational exposures and we focused on discerning potential modes of action reflecting biochemical charac teristics.
In vitro models have also been devel oped utilizing Ishikawa cells, a human endometrial cancer cell line. Boehme et al. (2009) (Boehme et al. 2009 ). Naciff et al. (2010) compared transcriptional profiles of ERαpositive Ishikawa cells treated with ethynyl E 2 or BPA for 8 hr, 24 hr, or 48 hr, with the focus on developing a relevant in vitro estrogen response model. These authors identified 307 commonly regulated probes as candidate biomarkers of potential estro genic activity. They further compared their BPAresponsive Ishikawa transcripts with uterine transcriptional profiles from juvenile rats dosed with estrogen for 8, 24, or 48 hr and observed 362 commonly regulated tran scripts (Naciff et al. 2010) . Using another approach, Bredhult et al. (2009) reported transcriptional analysis of primary cultures of human endometrial endothelial cells (HEEC) 24 hr after treatment with BPA, which led to decreased HEEC growth. They did not observe effects on known estrogenresponsive transcripts; however, because HEECs are ERα negative and express ERβ, responses might reflect, in part, ERβ targets. Abot et al. (2013) derived a panel of 40 estrogenresponsive tran scripts from published mouse uterus micro array data sets and also included evalua tion of phenotypic end points, including uterine weights and the proliferative marker Ki67. Their study was focused on the role of the AF1 domain of ERα in the uterus, which has been shown to be an AF1stimulated tissue (Arao et al. 2011) . Abot et al. (2013) were able to use tamoxifen (an AF1dependent estrogenic ligand) and mutations that disabled AF1 activity of the ERα to demonstrate roles of AF1 as illustrated by changes in transcrip tion or biological end points. However, these useful studies are not designed to further screen mechanisms underlying activity or potential biological outcomes.
Conclusion
The approach presented here (outlined in Table 1 ) could be used to evaluate poten tially estrogenic chemicals and could indicate possible biological mechanisms that would improve our understanding of the potential impacts on human health.
